Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season: Paris Tuesday, June 10, 2025, 11:00 Hrs [IST] Sanofi is shipp ...

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

Major vaccine policy changes could be on the horizon as the HHS removes key advisors. Click for my thoughts on what this may ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

As Head of R&D and a member of the Executive Leadership Team, the Company's research, development and medical affairs ...

ABUJA, NIGERIA / ACCESS Newswire / June 10, 2025 / In an era where healthcare disparities continue to challenge communities worldwide, five visionary pharmacists are making remarkable strides in revol ...